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Abstract
Background
Trypanosoma cruzi causes Chagas disease, an endemic and debilitating illness in Latin
America. Lately, owing to extensive population movements, this neglected tropical disease
has become a global health concern. The two clinically available drugs for the chemother-
apy of Chagas disease have rather high toxicity and limited efficacy in the chronic phase of
the disease, and may induce parasite resistance. The development of new anti-T. cruzi
agents is therefore imperative. The enzyme N-myristoyltransferase (NMT) has recently
been biochemically characterized, shown to be essential in Leishmania major, Trypano-
soma brucei, and T. cruzi¸ and proposed as promising chemotherapeutic target in these
trypanosomatids.
Methodology/Principal Findings
Here, using high-content imaging we assayed eight known trypanosomatid NMT inhibitors,
against mammal-dwelling intracellular amastigote and trypomastigote stages and demon-
strated that three of them (compounds 1, 5, and 8) have potent anti-proliferative effect at
submicromolar concentrations against T. cruzi, with very low toxicity against human epithe-
lial cells. Moreover, metabolic labeling using myristic acid, azide showed a considerable
decrease in the myristoylation of proteins in parasites treated with NMT inhibitors, providing
evidence of the on-target activity of the inhibitors.
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Conclusions/Significance
Taken together, our data point out to the potential use of NMT inhibitors as anti-T. cruzi
chemotherapy.
Author Summary
Trypanosoma cruzi is the etiological agent of Chagas disease, a chronic illness endemic to
Latin America. In recent years, this neglected infectious disease has also become a global
health concern due to the intense migratory flow of chronically affected individuals to
nonendemic regions such as the U.S. and Europe. The only available drugs against this dis-
ease have important disadvantages, such as, high toxicity, strain resistance, and variable
efficacy, underscoring the urgent need for new anti-T. cruzi agents. N-myristoyltransferase
(NMT) catalyzes the attachment of myristic acid, a fatty acid, to many proteins. In T.
cruzi, this enzyme appears to be essential, highlighting its potential as a drug target. In this
study, we show that NMT is expressed in all stages of the parasite and localized to the
endoplasmic reticulum. We also evaluate eight NMT inhibitors as anti-T. cruzi agents. We
demonstrate the efficacy of three of these compounds as anti-proliferative agents in this
intracellular parasite, while showing very low toxicity against mammalian cells. In addi-
tion, we provide evidence of the on-target effect of these compounds, thus demonstrating
their specificity and validating NMT as a drug target. These inhibitors hold great potential
for further exploration as anti-Chagas disease agents.
Introduction
The flagellate protozoan parasite, Trypanosoma cruzi, is the etiologic agent of Chagas disease (or
American trypanosomiasis), a neglected tropical disease widespread in Latin America. Accord-
ing to theWorld Health Organization (http://www.who.int/mediacentre/factsheets/fs340/en/),
currently there are 6–7 million individuals chronically infected, resulting in over 15,000 deaths
annually [1]. In recent years, Chagas disease has become an emerging public health concern in
the U.S. and other nonendemic countries such as Spain, due to the immigration of asymptomatic
infected individuals from endemic areas [2]. The current treatment for T. cruzi consists of two
nitroheterocyclic derivatives, benznidazole and nifurtimox, which are very effective in the acute
stage of the disease, but have limited efficacy in the chronic stage of the disease. Moreover, these
compounds may cause severe side effects and induce parasite strain resistance. Therefore, there
is an urgent need for new, more effective drugs to treat Chagas disease [3–5].
Myristoyl-CoA:protein N-myristoyltransferase (NMT) catalyzes the attachment of the fatty
acid myristic acid (C14:0) to the amino-terminal glycine residue of many eukaryotic proteins
[6]. NMT binds first to myristoyl-CoA, which results in a conformational change that allows
the target (poly)peptide to bind next. The myristoyl-CoA:NMT-(poly)peptide complex leads
to catalysis and the product, a N-myristoylated (poly)peptide, is released [7]. N-Myristoylation
is a ubiquitous co- and post-translational modification that is necessary for localization and
function of several proteins. Moreover, this modification increases the lipophilicity of proteins,
facilitating their association with membranes and promoting protein-protein interactions [8].
Myristoylation of several proteins involved in cellular regulation and signal transduction, such
as the α-subunit of several G proteins and cAMP-dependent protein kinases, has been shown
to be crucial for their function [9,10]. Protein myristoylation has been validated as an essential
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in Saccharomyces cerevisiae [11] and pathogenic fungi, such as Candida albicans,Histoplasma
capsulatum, and Cryptococcus neoformans [12]. Consequently, NMT has been explored as an
antifungal chemotherapeutic target [13]. Moreover, previous studies have identified NMT as
an attractive chemotherapeutic target against protozoan parasites including Leishmania dono-
vani, Leishmania major, Trypanosoma brucei, and Plasmodium falciparum [14–16]. More
recent detailed studies have validated NMT inhibitors, based on a pyrazole sulfonamide scaf-
fold, for the treatment of sleeping sickness [17], and malaria [18]. In T. cruzi, few N-myristoy-
lated proteins have been experimentally identified; examples include the phosphoinositide-
specific phospholipase C and the flagellar calcium-binding protein [19,20]. Nevertheless, bioin-
formatics analyses have predicted more than 100 proteins to be N-myristoylated [21]. In addi-
tion, for another post- translational modification, namely palmitoylation, to occur, prior
myristoylation is necessary for several important proteins. Palmitoylation, which is the linkage
of palmitic acid (C16:0) to cysteine residues, has been shown to be necessary for sorting to the
flagellar membrane in kinetoplastids [19,22]. Considering all these facts, it is expected that
NMT inhibition would have pleiotropic effects in the physiology of the parasite. Although this
enzyme has been extensively characterized in other kinetoplastids [14,16,23,24], very little is
known about T. cruzi NMT (TcNMT). In a recent study by Roberts et al. [25], attempts to gen-
erate a double-knockout mutants of TcNMT resulted always in retention of an endogenous
copy of the gene. Only in the presence of an ectopic, constitutively expressed NMT copy, was it
possible to achieve a double knockout. This strongly suggests that NMT is essential at least for
survival of the insect-derived noninfective epimastigote stage of the parasite. Moreover, when
epimastigotes were treated with the pyrazole sulfonamide inhibitor 2, there was a relationship
between the levels of NMT expression and the sensitivity of the parasites to this compound.
Parasites overexpressing NMT were significantly less sensitive to the compound thanWT par-
asites. Nonetheless, compound 2 was considerably less potent against T. cruzi epimastigotes in
contrast to T. brucei bloodstream forms, where this compound was curative in the mouse
model of human African trypanosomiasis (HAT). There could be several explanations for the
differences in potency: differences in the active site of NMT between these two organisms; dif-
ferences in compound uptake in the different parasites; or differences in the role of NMT in T.
brucei and T. cruzi.
Recently, inhibitors against T. brucei NMT (TbNMT) were identified through an initial
screening of 62,000 diversity-based compound library. Subsequent chemistry optimization of
the screening hit led to potent TbNMT inhibitors that prevented the proliferation of blood-
stream form of T. brucei with a window of selectivity of over 200-fold with respect to prolifera-
tion of mammalian cells [17,26,27]. Although these compounds presented high inhibition
both, in vitro and in vivo, against the extracellular bloodstream form of T. brucei, their effects
against intracellular parasites such as T. cruzi have not been elucidated. In this study, we evalu-
ated the effect of eight of these inhibitors, which exhibited EC50 values at the nanomolar range
against T. brucei [17,26], against mammal-dwelling intracellular amastigote and trypomasti-
gote stages of T. cruzi. Our results validate TcNMT as a potential chemotherapeutic target in
Chagas disease. Moreover, we determined the localization and expression of TcNMT through-
out the parasite life cycle.
Materials and Methods
Chemicals
Unless otherwise indicated, all reagents and solvents used here were of analytical, HPLC, or
mass-spectrometry grade from Sigma-Aldrich (St. Louis, MO), or from Thermo Fisher Scien-
tific (Waltham, MA).
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Mammalian cell culture and parasites
LLC-MK2 (green-monkey kidney epithelial cells) and U2OS (human osteocytes) (ATCC,
Manassas, VA) cells were culture in high-glucose Dulbecco’s Modified Eagle Medium
(DMEM), supplemented with 10% heat inactivated-fetal bovine serum (HI-FBS), at 37°C,
under 5% CO2 atmosphere. Tissue culture cell-derived trypomastigote forms of T. cruzi (TCT)
(Y strain) (ATCC) were obtained 5 to 9 days after infection of LLC-MK2 monolayers, as previ-
ously described [28]. T. cruzi epimastigotes (Epi) (Y strain) were maintained axenically in
liver-infusion tryptose (LIT) medium at 28°C, as previously described [29].
Purification of intracellular amastigote (ICA) forms
Intracellular amastigote (ICA) forms were purified as described [30,31]. Briefly, 5 x 106
LLC-MK2 cells were seeded in a 150-cm2 tissue culture flask (NUNC, Thermo Scientific) and
cells were grown for 3–4 days to reach confluency of ~2 x 107 cells per flask. The medium was
then replaced with fresh complete medium and host cells were infected with 1 x 108 TCT (mul-
tiplicity of infection (MOI) 5). After 5 days, the infected monolayers were gently detached by
scraping and resuspended in 5 mL phosphate-buffered saline (PBS). The suspension contain-
ing the infected cells was next transferred to an M-tube (Miltenyi Biotec Inc., San Diego, CA).
This tube bears a special stator and rotor that allows for tissue homogenization. In addition, it
has a pre-inserted mesh that retains larger particles, removing them from the homogenized
sample. The tube was then placed in the gentleMACS Dissociator (Miltenyi Biotec) for the
automated disruption of host cells. The homogenized sample containing the parasites was then
passed through a column containing anion exchange preswollen microgranular diethylami-
noethyl cellulose (DE52, Whatman, Sigma-Aldrich). The sialylated TCT forms of the parasites
were retained in the resin, while the ICA forms were recovered at 98–99% yield [30,31].
Indirect immunofluorescence assay
Parasites were washed with phosphate buffered saline (PBS), pH 7.4, and 1 x 104 cells per well
were deposited on a 96-well plate, followed by centrifugation at 3,000 xg for 10 min at room
temperature. Supernatant was removed and cells were fixed with 4% paraformaldehyde (PFA)
for 15 min at room temperature, then permeabilized with 0.1% Triton X-100 in PBS for 10 min.
Wells were blocked for 1h at room temperature with 3% bovine serum albumin (BSA) in PBS.
To obtain polyclonal anti-TcNMT, rabbit sera was rose against the TcNMT peptide
RGDGNLHYYFYNWSYP (Biomatik USA LLC., Wilmington, DE). Anti-TcNMT was labeled
with Alexa 594, while rabbit anti-TbBiP (a kind gift fromDr. James Bangs, University at Buffalo,
The State University of New York) was labeled with Alexa 488, using the APEX Antibody Label-
ing Kits (Invitrogen, Thermo Scientific) according to the manufacturer instructions. Parasites
were incubated overnight with the primary antibodies, both at 1:250 dilution in 3% BSA-PBS.
To remove unbound antibody, cells were washed 3x with PBS with 0.1% Tween (0.1% PBS-T).
Parasite DNA was then labeled with 4’,6-diamidino-2-phenylindole (DAPI) (Thermo Scientific)
at 0.5 μg/mL. Samples were visualized using a LSM 700 Confocal Microscope (Zeiss) with a 63X
oil objective lens. Images were acquired using the ZEN 2009 software (Zeiss).
Metabolic labeling
Parasites were washed with PBS three times and 1 x 107 cells were incubated at 37°C in the case
of ICA and TCT, and at 28°C in the case of Epi, in 1 mL of 2% delipidated BSA-DMEM. After
30 min, 100 μMClick-IT myristic acid, azide (Life Technologies, Thermo Fisher Scientific) was
added from 50 mM stock solutions in dimethyl sulfoxide (DMSO). The same volume of
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DMSO was used as a negative control. Parasites were further incubated for 6 h. For confocal
microscopy analysis, they were processed as described above. After permeabilization (0.1% Tri-
ton X-100 in PBS for 10 min, at room temperature), cells were washed three times with 3%
BSA in PBS. “Click” reaction between the myristic acid azide and Alexa Fluor 488 alkyne (Invi-
trogen) was performed according to the manufacturer instructions using the Click-iT Cell
Reaction Buffer Kit (Invitrogen). Parasite DNA was labeled with DAPI. Samples were visual-
ized and images acquired as described above.
In vitro parasite proliferation assay
Compounds 1–8 were synthesized at the University of Dundee Drug Discovery Unit [17,25–
27,32]. These DDD compounds and the reference drug benznidazole (BZ) (Sigma-Aldrich,
St. Louis, MO) were prepared 6-fold-concentrated in 6% DMSO, to give a final concentration
of 1x compound in 1% DMSO. Thirty microliters of each DDD compound were added to a
96-well microplate (Nunc, Thermo Scientific) to give the final concentrations of 50, 10, 1, 0.1,
0.01, and 0.001 μM, whereas BZ was added at the final concentrations of 800, 400, and 40 μM.
DMSO control wells contained 30 μL 6% DMSO. Human osteocytes (U2OS cells) were diluted
in DMEM, 10% heat inactivated-fetal bovine serum (HI-FBS) to give a cell density of 2 x 105
cells/mL. T. cruzi trypomastigotes were resuspended in DMEM, 10% HI-FBS to a final density
of 1.2 x 107. Cells and parasites were mixed a ratio of 4 volumes of cells plus 1 volume of para-
sites. 150 μL of the mixture were dispensed per well. Plates were incubated for 48 h. After the
incubation period, media was removed from the wells and 100 μL 4% paraformaldehyde (PFA)
were added. After 15 min of incubation at room temperature, PFA was removed and cells and
parasites were stained with Draq5 (BioStatus, Leicestershire, UK) at a concentration of 5 μM
diluted in PBS. The plates were then read in a bioimager system as described below. Three
independent experiments were performed in triplicate wells.
High-content imaging (HCI) assay
Image acquisition and analyses of the plates were carried out using the BD Pathway 855 high-
resolution fluorescence bioimager system (BD Biosciences, San Jose, CA), as previously
described [33]. Filter sets appropriate for the excitation and emission spectra of Draq5 were
utilized. Images from four fields (2 x 2 montage) were acquired per well with a 20x objective.
To perform the host cell segmentation and counting of parasites, the BD AttoVision v1.6.2 Sub
Object analysis was used. Draq5 creates a background, staining the host cell and parasite
nucleus, but defining the cytoplasm as well, determining this way the amount of parasites
within each mammalian cell. The host cell nucleus was excluded by size difference. Raw data
was imported into the BD Image Data Explorer (BD Biosciences) to determine the percentage
of infected cells containing at least 1, at least 3 or at least 5 intracellular parasites.
Cytotoxicity assay
DDD compounds 1–8 and the reference drug BZ were prepared 6-fold-concentrated in 6%
DMSO, to give a final concentration of 1x compound in 1% DMSO. Thirty microliters of each
compound were added to give the final concentrations of 50, 10, 1, 0.1 and 0.01 μM. DMSO con-
trol wells contained 30 μL 6% DMSO, whereas wells for the negative control contained 1%
hydrogen peroxide in DMEM. U2OS cells were resuspended in DMEM, 10% HI-FBS, to give a
cell density of 2 x 105 cells/mL, while ICA forms were resuspended in DMEM, 10% HI-FBS, to a
final density of 1 x 107 per well. Epi forms were resuspended in LIT medium to a density of 1 x
106 parasites per well. Hundred and fifty microliters of the suspension containing either host
cells or parasites were added per well. Following 47- and 23-h incubation at 37°C for mammalian
Trypanosoma cruzi N-myristoyltransferase Inhibitors
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cells and ICA, respectively, a mixture of propidium iodide (Invitrogen) and Hoechst dye (Invi-
trogen) diluted in culture media (1 μg/mL each) was added to the plates, which were then further
incubated for 1 h at 37°C. Finally, plates were read in the BD Pathway 855 bioimager system. In
the case of Epi, after 68-h incubation at 28°C, 18 μL Alamar Blue (AbD Serotec, Raleigh, NC)
were added per well. Following an additional 4-h incubation, the plate was read in a microplate
fluorometer (Thermo Scientific) at excitation 560 nm, emission 590 nm. Three independent
experiments were performed in triplicate wells.
Determination of EC50
The half maximal effective concentrations (EC50) were determined using GraphPad software
(GraphPad Software, Inc., La Jolla, CA) using a sigmoidal dose-response variable slope model
with response values based on the total number of parasites or cells (normalized to span de
range from 0 to 100%) plotted against the logarithm of compound concentration. EC50 were
determined from three independent experiments.
In-gel western blotting
Parasites were incubated with or without 10 μM of the inhibitor 1, 5, or 8 in 1 mL 2% delipi-
dated BSA-DMEM at 37°C for ICA and TCT and at 28°C for Epi. After 6 h, 100 μMmyristic
acid, azide (from a 50-mM stock in DMSO) were added to the samples, and the same volume
of DMSO was added to the negative control. Cells were incubated for another 6 h, for a 12-h
treatment with the inhibitors. Next, the parasites were washed three times with PBS and lysed
in 1% SDS, Tris-HCl, pH 8.0. “Click” reaction was performed between the myristic acid azide
and Biotin Alkyne (Invitrogen) according to the manufacturer instructions using the Click-iT
Protein Reaction Buffer Kit (Invitrogen). Duplicate aliquots of lysates were ran in 10%
SDS-PAGE followed by fixing (5% acetic acid, 50% isopropanol) for 15 min. Gels were then
analyzed by in-gel western blotting using IRDye streptavidin (LI-COR Biosciences, Lincoln,
NE) 1:7500 in 5% BSA, 0.05% SDS, 0.2% Tween in PBS, for 1 h at room temperature. They
were subsequently treated or not with 0.2 M NaOH in methanol for 1 h at room temperature.
Gels were scanned in an ODYSSEY quantitative imagining system (LI-COR Biosciences). They
were next stained with Coomassie blue and scanned again to determine total protein levels.
[35S]-Methionine labeling
Parasites were incubated with or without 10 μM of the inhibitors as described above. After 10
h, cells were starved in methionine deficient media for 1 h. Next, 20 μCi.mL-1 [35S]-methionine
(Perkin Elmer) were added to the samples for 1 h incubation, for a 12-h treatment with the
inhibitors. Next, the parasites were washed three times with PBS and lysed in 1% SDS, Tris-
HCl, pH 8.0. Samples were ran in 4–12% gels (Expedeon, San Diego, CA) and transferred to
polyvinylidene fluoride (PVDF) membranes (Sigma-Aldrich). Membranes were dried and
exposed to Hyperfilm ECL (Amersham, GE Healthcare Lifesciences, Piscataway, NJ). To deter-
mine total protein levels, membranes were stained with Ponceau S after exposure.
Western blotting analysis
Parasites (1 x 107 cells) were incubated with or without 10 μM of the inhibitor (compound 1, 5,
or 8) in 1 mL 10%HI-FBS, DMEM at 37°C for ICA and TCT, and at 28°C for Epi for 12 h. Next,
parasites were washed three times with PBS and lysed in 1% SDS, Tris-HCl, pH 8.0. Samples were
run in 10% SDS-PAGE followed by western blot probed with anti-TcNMT at dilution 1:1000 in
5%milk-PBS overnight. This was followed by incubation with anti-rabbit IgG-HRP conjugated.
Trypanosoma cruzi N-myristoyltransferase Inhibitors
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The membrane was next stripped with boiling stripping buffer (3% SDS, 0.3% β-mercaptoetha-
nol) for 10 min, followed by 4 washes with 0.1% PBS-T. It was then blot again with anti-BiP at
dilution 1:500 in 5%milk-PBS overnight, at 4°C, followed by anti-rabbit IgG HRP-conjugated.
Results
NMT expression and localization in T. cruzi
To investigate the expression and cellular localization of TcNMT during the T. cruzi life cycle,
epimastigote (Epi), intracellular amastigote (ICA), and tissue cell culture-derived trypomasti-
gote (TCT) forms were analyzed by immunofluorescence, using an antiserum (anti-TcNMT)
obtained in rabbit against the TcNMT peptide RGDGNLHYYFYNWSYP. Anti-TcNMT
showed that NMT has a punctate pattern in Epi and TCT and more diffused labeling in ICA.
In all three stages, however, there is little or no labeling localized to the nucleus and kinetoplast.
The results indicate that the anti-TcNMT labeling is mostly associated with the endomembrane
system and other intracellular sites in the parasite. To further determine the subcellular locali-
zation of TcNMT we use anti-TbBiP as an endoplasmic reticulum (ER) marker [34]. Colocali-
zation with BiP suggests that NMT is at least partially associated to the ER of T. cruzi (Fig 1).
Taken together, these results demonstrate that TcNMT is constitutively expressed in all the
stages of the T. cruzi life cycle, as previously shown by Roberts et al. using immunoblots of
crude lysates [25], and that it is associated with the ER. To determine the specificity of anti-
TcNMT, human osteocytes were infected with T. cruzi and analyzed by immunofluorescence.
Anti-TcNMT readily labeled intracellular parasites at 72-h (ICA) and 96-h (mostly TCT) post-
infection, whereas non-infected cells were not labeled, indicating that there is no cross-reactiv-
ity between this antiserum and human cells (Fig 2).
TcNMT shares 59% and 57% overall amino acid identity with NMTs from T. brucei and L.
major, respectively. Antiserum against LmNMT and antiserum against TbNMT also recognized
TcNMT in Epi (S1 Fig). The expression and distribution of TcNMT is consistent with that
observed in L.major and T. brucei [23,24], where NMT is also expressed in both the insect-vector
and the mammalian forms of the parasites. Sequence analysis showed that similarly to TbNMT
and LmNMT, TcNMT is divergent in its N-terminus from all NMTs so far characterized. Inter-
estingly, even though our data suggest ER association, TcNMT does not contain the lysine-rich
regions that have been associated with ribosomal targeting in human and mouse NMTs [35].
NMT residues that have been predicted to be essential for the activity of this enzyme,
including the two negatively charged residues, Leu 452 and Glu 173, that have been predicted
to form the floor of the active site pocket in C. albicans NMT [6,36], are conserved in TcNMT.
An insertion of 22- or 20-mer is found close to the first “pocket floor” in TbNMT and
LmNMT, respectively, relative to human and fungal NMTs [23]. In the same region, between
the residues Arg 129 and Leu 164, a 34-mer insertion is observed in TcNMT, but completely
absent in human NMT (HsNMT). An additional insertion in TcNMT (between Glu 324 and
Gln 347) and TbNMT is found further downstream, but completely absent in LmNMT and
HsNMT. These differences between protozoan, fungal, and human NMTs suggest that the
enzyme activity might be affected by additional secondary or tertiary structures formed in
these parasites NMTs relative to human and fungal enzymes (Fig 3).
Myristic acid azide-labeled proteins are associated with the
endomembrane system
It has been shown that metabolic labeling with azido-fatty acid analogs followed by “click”
reaction with an alkyne-containing fluorophore, results in fluorescently labeled fatty-acylated
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proteins [37]. To visualize the distribution of N-myristoylated proteins we first labeled Epi,
ICA, and TCT with myristic acid, azide. This azide tag is small enough to permit the incorpo-
ration of the tagged myristic acid molecule onto proteins by NMT and has recently been
shown to efficiently label N-myristoylated proteins in T. cruzi Epi forms [25]. Previous studies
have shown that treatment with Triton X-100 solubilizes and extracts fatty acid chemical
reporters that are not covalently attached to proteins [37]. After fixing, we then permeabilized
parasite cells with Triton X-100 and performed chemoselective ligation or “click” chemistry
between the azide and Alexa Fluor 488 alkyne. By following this protocol, we could ensure that
the majority of the Alexa Fluor 488 signal corresponds mostly to putative N-myristoylated pro-
teins. The confocal microscopy showed mainly a punctate pattern in all three T. cruzi life-stage
forms, indicating endomembrane association (Fig 4). Overall, these results are consistent with
the notion that N-myristoylation targets proteins to membranes [38].
DDD compounds inhibit T. cruzi intracellular proliferation
Previous studies demonstrated the efficacy of the studied pyrazole sulfonamides as NMT inhib-
itors against T. brucei infective bloodstream forms [17,26] and T. cruzi noninfective Epi forms
[25]. However, there have been no reports on the activity of these compounds against the
human-disease relevant (ICA and TCT) stages of T. cruzi. Here, we tested selected NMT inhib-
itors to determine their effects against the intracellular proliferation of T. cruzi in human
Fig 1. TcNMT is constitutively expressed in all T. cruzi stages and it is associated to the endoplasmic reticulum. Immunofluorescence microscopy of
Epi, ICA, and TCT. Cells are shown as viewed under phase contrast, visualized for fluorescence with anti-TcNMT (red) and anti-BiP (green), co-stained with
DAPI to reveal positions of the nucleus and kinetoplast (blue). Scale bar, 2 μm.
doi:10.1371/journal.pntd.0004540.g001
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osteocytes (U2OS cells). Draq5 stains nucleic acids; however, it creates a background defining
the cytoplasm of the host cell. Therefore, it stains the nucleus of the host cell and the parasite
with a higher intensity, while staining the cytoplasm of the mammalian cell with a fainter
intensity, rendering the software able to distinguish one from the other. An example of the seg-
mentation performed on the fluorescence bioimager is shown in Fig 5A. Upon entering the
cell, trypomastigotes differentiate into replicative amastigote forms, which then begin to divide.
Approximately 96 h after infection the parasite transforms again into trypomastigotes, finally
rupturing the cell and releasing the parasites into the extracellular milieu [39]. Since we are
interested in the antiproliferative effects of the compounds, we incubated for 48 h prior to fixa-
tion. At this time point, significant replication of the parasite is observed with little host-cell
disruption. To determine the percentage of infected cells, we evaluated cells containing at least
one parasite (S2A and S2B Fig). We did not see significant differences in the number of
infected cells between the untreated wells and the wells treated with the compounds below
10 μM concentration. To determine the proliferation inside the mammalian cells, the number
of cells containing at least 3 (S2C and S2D Fig) or 5 (Fig 5B) parasites was plotted. Compounds
1, 5 and 8 were able to inhibit intracellular amastigote proliferation at submicromolar
Fig 2. Anti-TcNMT shows no cross-reactivity with human cells. Immunofluorescence microscopy of non-infected and infected cells 72- and 96-h post-
infection stained with anti-TcNMT (red), co-stained with DAPI (blue) to visualize host cell and parasite DNA. Scale bar, 10 μm.
doi:10.1371/journal.pntd.0004540.g002
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concentrations, with EC50 values of 0.18 μM, 0.26 μM, and 0.35 μM, respectively, with selectiv-
ity index (S.I.) of 71, 44, and 33, respectively (Fig 6; bold, underlined numbers). Although com-
pounds 4 and 6 also exhibited submicromolar EC50 values (0.54 and 0.99 μM, respectively) and
good S.I. (>93 and>51, respectively) in the T. cruzi proliferation assay, they were not effective
against purified ICAs (EC50>50 μM) (Fig 6). Therefore, they were not further analyzed here as
potential anti-T. cruzi agents.
DDD compounds are trypanocidal and nontoxic to mammalian cells
These compounds were originally synthesized to target an extracellular parasite, namely T. bru-
cei. Therefore, we wanted to determine if the cytotoxic effects against the intracellular parasite
T. cruzi could be increased once the barrier of host cell membrane was not present. If com-
pound access to the parasites proved problematic, understanding what properties in the com-
pound are important for access to the intracellular parasites would assist compound design
and selection. To determine the effects directly on ICA forms, we purified them from the host
Fig 3. Alignment of T. cruzi NMTwith NMTs from T. brucei, L.major and human. The deduced open reading frame of TcNMT (AI069625) was aligned
with TbNMT (TRYP10.0.001826–6), LmNMT (AF3059561), and human NMT (HsNMT) (HUMAN, P30419) using the ClustalW2 multiple sequence alignment
program (http://www.ebi.ac.uk/Tools/msa/clustalw2/). Strictly conserved residues are shown in red. The insertions in protozoan NMTs (TcNMT, TbNMT, and
LmNMT) are underlined. Red boxes indicate key residues involved in myristoyl-CoA binding; black boxes indicate residues involved in peptide binding
identified in yeast species. Arrows identify the pocket floor residues inC. albicans.
doi:10.1371/journal.pntd.0004540.g003
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cells and incubated them with the inhibitors for 24 h. As expected, compounds 1, 5, and 8,
which were the most effective at inhibiting proliferation, were also the most cytotoxic against
purified ICA forms, exhibiting an EC50 of 1.8 μM, 0.06 μM, and 0.02 μM, respectively (Figs 6
and 7A). We were able to see a more potent effect of the inhibitors 5 and 8 when tested directly
against ICA. This suggests that by improving the translocation of these two compounds into
the mammalian host cell, the potency of the inhibitors against the intracellular parasites would
be enhanced. Compound 2 had shown high efficacy against T. brucei, both in vitro and in vivo
[17]. Interestingly, in T. cruzi this compound exhibited an EC50 of 1.1 μM (Fig 5B) in the pro-
liferation assay and showed no significant trypanocidal activity against purified ICA forms (S3
Fig). Intriguingly, the Epi forms were less susceptible to these compounds. No significant dif-
ference was observed on the viability of the Epi forms of the parasite when increasing the
length of the treatment from 48 to 72 h. After 72 h, compound 1 did not have a significant
effect on parasite viability, whilst compounds 5 and 8 showed an EC50 of 9.7 μM and 2.1 μM,
respectively (Fig 7B).
To determine the cytotoxic effects of these compounds on mammalian cells, we performed
a viability assay on U2OS cells. Using high-content imaging, we were able to differentiate dead
cells by the uptake of propidium iodide. The EC50 on U2OS of all three compounds were above
10 μM (Fig 6). After 48 h of treatment, compounds 1, 5, and 8 showed toxicity only at 50 μM,
while there was no significant effect at lower concentrations (S4 Fig). Since almost complete
Fig 4. Myristoylated proteins are associated to the endomembrane system. Fluorescence microscopy of Epi, ICA, and TCTmetabolically labeled with
myristic acid, azide were reacted with Alexa 488 alkyne (green) after permeabilization, co-stained with DAPI (blue) to label the nucleus and kinetoplast. Scale
bar, 5 μm.
doi:10.1371/journal.pntd.0004540.g004
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inhibition of intracellular proliferation of the parasite was observed at concentrations as low as
10 μM, there is a window of selectivity between parasite and mammalian cells (Fig 6).
Inhibitors act “on target”
To determine whether these inhibitors are acting on TcNMT, we labeled Epi, ICA and TCT
forms with myristic acid azide, which had been previously incubated with or without 10 μM of
each inhibitor. Detection of N-myristoylated proteins is typically performed by metabolic label-
ing with radioactive [3H]-myristate [17]. Alternatively, here we used a biorthogonal labeling
method. In the first step, an azido-myristic acid analog was actively incorporated into the para-
sites. In the second step, the “click” reaction, the azide-modified proteins reacted with a chemo-
selective alkyne-biotin. After SDS-PAGE and in-gel western blot analysis with IRDye 800CW
Streptavidin, several putative N-myristoylated proteins were visualized in Epi, ICA, and TCT
(Fig 8, Untreated). To confirm that these proteins were indeed N-myristoylated a representa-
tive duplicate gel of Epi lysate was treated with 0.2 M NaOH in methanol to remove any base-
labile hydroxy- or thioester-linked myristic acid azide. Treatment of putative Epi N-myristoy-
lated proteins with base prior to scanning showed no difference in the number and intensity of
bands indicating that they are N-myristoylated proteins (S5 Fig). Two bands, at approximately
Fig 5. DDD compounds inhibit intracellular proliferation of T. cruzi. (A) Representative images of cells treated with the vehicle control (DMSO),
untreated, treated with 800 μM benznidazole (BZ) or 10 μM compound 8, stained with Draq5 (left panel), and analyzed by HCI. Artificial images created after
segmentation on the fluorescence bioimager (right panel). Host cells are shown in blue, extracellular parasites in red and intracellular parasites in pink. (B)
The multiparametric data obtained on a cell-by-cell basis by HCI was analyzed to determine several parameters associated to infection of host cells by T.
cruzi including the percentage of cells infected with at least five parasites (percentage of cells in which the parasite proliferated), treated or not with DDD
compounds 1–8. C, controls: 40, 400, and 800 μMBZ, DMSO, and Untreated.
doi:10.1371/journal.pntd.0004540.g005
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70 and 250 kDa, were present in all samples from Epi, ICA, and TCT (Fig 8). They probably
represent proteins that are endogenously biotinylated; such as the biotin-dependent carboxyl-
ases, 3-methylcrotonyl-CoA and acetyl-CoA carboxylase which have been extensively charac-
terized in T. brucei [40]. Incubation of the parasites with 10 μM of compound 1, 5, or 8 for 12 h
resulted in either a decreased intensity or complete loss of most of the bands in all the stages of
Fig 6. EC50 values and selectivity index (S.I.) of DDD compounds in noninfected and T. cruzi-infected
U2OS cells, and purified intracellular amastigotes. (a and b) Non-infected and infected U2OS cells,
respectively, were incubated for 48 h at 37°C with DDD compounds 1–8. (c) Purified ICAs were incubated for
24 h at 37°C with DDD compounds 1–8. (d) Not determined.
doi:10.1371/journal.pntd.0004540.g006
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the parasite (Fig 8). To determine whether these compounds specifically inhibited N-myristoy-
lation, parasites from the three different stages of T. cruzi were labeled with [35S] methionine
[17]. Treatment with compound 1, 5, or 8 had no effect on the incorporation of [35S]-methio-
nine into proteins (S6 Fig), indicating that the inhibitors do not affect protein translation.
Taken together, these results suggest that the DDD compounds specifically inhibit N-myristoy-
lation in all T. cruzi stages and that this is directly linked to inhibition of proliferation.
Epimastigotes treated with DDD compounds overexpress NMT
To investigate the expression and cellular localization of TcNMT in parasites treated with the
compounds, Epi, ICA, and TCT were analyzed by western blotting after 12 h of treatment with
10 μM of compound 1, 5, or 8. TcNMT in lysates from wild-type parasites could not be
detected by western blotting, probably due to low expression in all stages of T. cruzi. However,
Epi treated for 12 h with 10 μM of compounds showed an overexpression of TcNMT that was
detectable (Fig 9). We were unable to see the same phenomenon in lysates from ICA and TCT
forms pre-incubated with the DDD compounds. Moreover, these observations may explain the
increased resistance of Epi to the inhibitors (Fig 7B). Even though we still see a reduction in
Fig 7. DDD compounds are trypanocidal against purified intracellular amastigotes. Total number of
parasites in each well was counted to evaluate the cytotoxicity of the compounds 1, 5, and 8 against purified
ICA (A) and Epi (B). C, controls: Untreated, DMSO, and H2O2.
doi:10.1371/journal.pntd.0004540.g007
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protein N-myristoylation in Epi (Fig 8), the overexpression of TcNMTmight be enough to
compensate for the inhibitory effects of the compounds, rendering these parasites less suscepti-
ble to the treatment. Encouragingly, these data further confirm the “on-target” effect of these
compounds.
Discussion
Despite the impressive advances in understanding the protozoan parasite T. cruzi, Chagas dis-
ease continues to cause significant morbidity and mortality. The two drugs available to treat
this disease (i.e., benznidazole and nifurtimox) are decades old, limited in efficacy, and present
Fig 8. DDD compounds specifically inhibit TcNMT. In-gel western blots of lysates of (A) Epi, (B) ICA, and (C) TCT treated or not with 10 μM of the DDD
inhibitor 1, 5, or 8, labeled with myristic acid, azide followed by “click” reaction with biotin alkyne. IRDye 800CW streptavidin was used to detect myristoylated
proteins. Arrows indicate protein bands whose labeling was more affected by any of the DDD compounds tested.
doi:10.1371/journal.pntd.0004540.g008
Fig 9. TcNMT is overexpressed in epimastigotes treated with DDD compounds. Epi forms were treated
for 12 h with or without 10 μM of compound 1, 5, or 8. Levels of NMT expression were confirmed by western
blotting using anti-TcNMT. BiP (binding protein) was used as a loading control.
doi:10.1371/journal.pntd.0004540.g009
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severe side effects. Moreover, there is no vaccine available. Chagas disease is therefore classified
as a neglected tropical disease. Accordingly, there is an urgent need for new chemotherapeutic
targets and approaches aiming at the development of novel compounds against this parasite
[3–5]. Here, we present data that validates T. cruzi N-myristoyltransferase as a potential che-
motherapeutic target in mammal-dwelling stages of the parasite. N-myristoyltransferase has
been intensively studied as a drug target for fungal and parasitic infections [41–44]. Nonethe-
less, despite the obvious importance of this lipid modification in T. cruzi, until recently no
much effort has been taken in exploring TcNMT as a potential drug target in Chagas disease. A
recent study by Roberts et al. [25], however, has performed the first molecular and biochemical
characterization of TcNMT. These authors showed that NMT is found in crude lysates of all
stages of T. cruzi. When they tried to knockout the two copies of the TcNMT, they found that
was only feasible if an ectopic copy of the gene was constitutively expressed by the parasite.
These results clearly point out to the importance of the NMT for the survival of the noninfec-
tive epimastigote form of the parasite. In that study, the pyrazole sulfonamide NMT inhibitor 2
was tested with the recombinant enzyme and epimastigotes. Although that drug showed potent
in vitro and in vivo inhibitory activity against T. brucei, its inhibitory activity in T. cruzi was
considerably much lower. This compound was 13- to 23-fold less potent against recombinant
TcNMT than TbNMT, and ~1,000-fold less potent against epimastigotes than was previously
reported for T. brucei [25]. This discrepancy in drug potency against the enzymes might be
caused by the dissimilarities in the amino acid composition surrounding the active site of the
two NMT orthologs.
In the present study, the amino acid sequence analysis clearly showed conservation of resi-
dues predicted to be essential for NMT activity. Interestingly, two 30- and 22-mer insertions
located at the N-terminus and C-terminus, respectively, are found in TcNMT, suggesting addi-
tional secondary and tertiary structures that could affect TcNMT activity relative to TbNMT,
LmNMT, and human NMT (HsNMT). The first insertion located near to N-terminus is also
present but shorter in TbNMT and LmNMT; the second, although present and longer
(28-mer) in TbNMT, is clearly absent in LmNMT. These differences between different proto-
zoan and human NMTs could eventually be exploited in the development of specific NMT
inhibitors. NMTs from L.major and T. brucei have been shown to partition between mem-
brane and cytosolic fractions [14,24]. Here, we show by colocalization with BiP that TcNMT is
at least partially associated to the ER. Moreover, we provide evidence that NMT is constitu-
tively expressed, and most importantly present in those stages (i.e., ICA and TCT) of T. cruzi
that maintain the disease chronic in mammals, further highlighting the importance of this
enzyme.
Screening of a 62,000 diversity-based compound library against T. brucei NMT, followed by
a subsequent chemistry optimization program, led to the discovery of potent inhibitors that
cured African trypanosomiasis in vivo [17]. In this study, we tested eight inhibitors against
intracellular (ICA and TCT) forms T. cruzi. We presented evidence of strong inhibition of
intracellular amastigote proliferation particularly with compounds 1, 5, and 8. Importantly,
they did not show cytotoxic effects against mammalian cells at effective trypanocidal concen-
trations. Interestingly, in our study compound 2 showed no trypanocidal activity against puri-
fied ICA. In contrast, treatment with compound 2 resulted in rapid killing of T. brucei
trypanosomes both in vivo and in vitro [17]. For reasons that are not completely understood,
T. brucei appears to be hypersensitive to NMT inhibition. Treatment with compound 2 in T.
brucei results in the “BigEye” phenotype, where endocytosis is disturbed, leading to expansion
of the flagellar pocket. As extensively discussed by Roberts et al. [25], the differences in suscep-
tibility to NMT inhibition between T. cruzi and T. brucei could be due to differences in endocy-
tosis or in the rate of plasma membrane turnover between these two species. Additionally,
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differences in cellular uptake and efflux of the inhibitors, as well as, differences in essential bio-
logical functions requiring N-myristoylation, could also play a role in the decreased potency of
DDD compounds against T. cruzi.
In addition, we have demonstrated the “on target” effect of these compounds by metabolic
labeling with myristic acid, azide. In-gel western blots of lysates from parasites showed a signif-
icant decrease in protein N-myristoylation relative to the untreated controls. Strikingly, Epi
were less susceptible to these compounds, which might be explained by the TcNMT overex-
pression observed in this stage of the parasite. This overexpression suggests a compensation
mechanism for the inhibition of TcNMT, confirming the specificity of the inhibitors. Overall,
it is likely that the effects of the tested compounds are a result of several downstream events, as
this enzyme has over 100 putative substrates [21]. The lead compounds hold great potential to
be explored as anti-Chagas disease agents.
Supporting Information
S1 Fig. Anti-LmNMT and anti-TbNMT recognize TcNMT. Immunofluorescence micros-
copy of Epi stained with anti-LmNMT and anti-TbNMT (red), co-stained with DAPI (blue) to
reveal positions of the nucleus and kinetoplast (blue). Scale bar, 5 μm.
(TIF)
S2 Fig. DDD compounds inhibit intracellular proliferation of T. cruzi. The multiparametric
data obtained on a cell-by-cell basis by HCI was analyzed to determine several parameters asso-
ciated to infection of host cells by T. cruzi. (A and B) Percentage of cells infected with at least
one parasite (percentage of infected cells). (C andD) Percentage of cells infected with at least
three parasites (percentage of cells in which the parasite proliferated). C, controls: BZ (800,
400, and 40 μM), Untreated, and DMSO.
(TIF)
S3 Fig. DDD compound 2 is not trypanocidal against purified intracellular amastigotes.
Total number of cells in each well was counted by HCI to evaluate the cytotoxicity of the com-
pound 2 against purified ICA forms. C, controls: Untreated, DMSO, and H2O2.
(TIF)
S4 Fig. DDD compounds are toxic against mammalian cells only at high concentrations.
Total number of cells in each well was counted by HCI to evaluate the cytotoxicity of the com-
pounds 1, 5, and 8 against U2OS cells. C, controls: Untreated, DMSO, and H2O2.
(TIF)
S5 Fig. T. cruzimyristoylated proteins are not susceptible to base treatment. In-gel western
blot of Epi lysate was treated (+ NaOH) or not (- NaOH) with 0.2 M NaOH in methanol to
remove any base-labile hydroxy- or thioester-linked myristic acid azide, followed by “click”
reaction with biotin alkyne. IRDye 800CW streptavidin was used to detect myristoylated pro-
teins.
(TIF)
S6 Fig. DDD compounds do not affect protein translation. Fluorographs of PVDF mem-
branes of [35S]-methionine-labeled lysates from Epi, ICA, and TCT forms treated or not with
10 μM of the compound 1, 5, or 8.
(TIF)
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